Approval · Notice of Compliance 18434 · 2016
XIAFLEX: Notice of Compliance 18434
Issued September 2, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18434
- Date
- September 2, 2016
- Company
- Endo Ventures Ltd
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Transfer of drug identification number
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| XIAFLEX | 02388316 | Cancelled Post Market |
Medicinal ingredients
- COLLAGENASE CLOSTRIDIUM HISTOLYTICUM 0.9 MG per VIAL